Literature DB >> 23411394

Can we prevent Alzheimer's disease? Secondary "prevention" trials in Alzheimer's disease.

Maria C Carrillo1, H Robert Brashear, Veronika Logovinsky, J Michael Ryan, Howard H Feldman, Eric R Siemers, Susan Abushakra, Dean M Hartley, Ronald C Petersen, Ara S Khachaturian, Reisa A Sperling.   

Abstract

Current research including the basic biology of Alzheimer's disease (AD) provides a foundation to explore whether our current state of knowledge is sufficient to initiate prevention studies and allow us to believe prevention of AD is possible. Current research and recently revised criteria for the diagnosis of AD by the National Institutes on Aging and the Alzheimer's Association suggest a continuum of disease from preclinical asymptomatic to symptomatic Alzheimer's dementia. In light of these revised criteria, the possibility of secondary prevention and even primary prevention is under discussion. The Alzheimer's Association Research Roundtable convened a meeting to discuss the rationale and feasibility of conducting secondary prevention trials in AD.
Copyright © 2013 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23411394     DOI: 10.1016/j.jalz.2012.12.004

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  48 in total

1.  A noninflammatory immune response in aged DNA Aβ42-immunized mice supports its safety for possible use as immunotherapy in AD patients.

Authors:  Doris Lambracht-Washington; Roger N Rosenberg
Journal:  Neurobiol Aging       Date:  2014-12-12       Impact factor: 4.673

2.  Design and sample size considerations for Alzheimer's disease prevention trials using multistate models.

Authors:  Ron Brookmeyer; Nada Abdalla
Journal:  Clin Trials       Date:  2019-04       Impact factor: 2.486

3.  Expanding engagement with the ethical implications of changing definitions of Alzheimer's disease.

Authors:  Richard Milne; Jason Karlawish
Journal:  Lancet Psychiatry       Date:  2017-04       Impact factor: 27.083

4.  Practical risk score for 5-, 10-, and 20-year prediction of dementia in elderly persons: Framingham Heart Study.

Authors:  Jinlei Li; Matthew Ogrodnik; Sherral Devine; Sanford Auerbach; Philip A Wolf; Rhoda Au
Journal:  Alzheimers Dement       Date:  2017-06-13       Impact factor: 21.566

5.  Advances in the prevention of Alzheimer's disease and dementia.

Authors:  A Solomon; F Mangialasche; E Richard; S Andrieu; D A Bennett; M Breteler; L Fratiglioni; B Hooshmand; A S Khachaturian; L S Schneider; I Skoog; M Kivipelto
Journal:  J Intern Med       Date:  2014-03       Impact factor: 8.989

6.  Stop Alzheimer's before it starts.

Authors:  Eric McDade; Randall J Bateman
Journal:  Nature       Date:  2017-07-12       Impact factor: 49.962

Review 7.  Ethical issues in neurogenetics.

Authors:  Wendy R Uhlmann; J Scott Roberts
Journal:  Handb Clin Neurol       Date:  2018

8.  Dementia Prevention: optimizing the use of observational data for personal, clinical, and public health decision-making.

Authors:  Penny A Dacks; Sandrine Andrieu; Deborah Blacker; Aaron J Carman; Allan M Green; Francine Grodstein; Victor W Henderson; Bryan D James; Rachel F Lane; Joseph Lau; Pei-Jung Lin; Barnaby C Reeves; Raj C Shah; Bruno Vellas; Kristine Yaffe; Karin Yurko-Mauro; Diana W Shineman; David A Bennett; Howard M Fillit
Journal:  J Prev Alzheimers Dis       Date:  2014-02

9.  Identifying postmenopausal women at risk for cognitive decline within a healthy cohort using a panel of clinical metabolic indicators: potential for detecting an at-Alzheimer's risk metabolic phenotype.

Authors:  Jamaica R Rettberg; Ha Dang; Howard N Hodis; Victor W Henderson; Jan A St John; Wendy J Mack; Roberta Diaz Brinton
Journal:  Neurobiol Aging       Date:  2016-01-29       Impact factor: 4.673

10.  MAPT STUDY: A MULTIDOMAIN APPROACH FOR PREVENTING ALZHEIMER'S DISEASE: DESIGN AND BASELINE DATA.

Authors:  B Vellas; I Carrie; S Gillette-Guyonnet; J Touchon; T Dantoine; J F Dartigues; M N Cuffi; S Bordes; Y Gasnier; P Robert; L Bories; O Rouaud; F Desclaux; K Sudres; M Bonnefoy; A Pesce; C Dufouil; S Lehericy; M Chupin; J F Mangin; P Payoux; D Adel; P Legrand; D Catheline; C Kanony; M Zaim; L Molinier; N Costa; J Delrieu; T Voisin; C Faisant; F Lala; F Nourhashémi; Y Rolland; G Abellan Van Kan; C Dupuy; C Cantet; P Cestac; S Belleville; S Willis; M Cesari; M W Weiner; M E Soto; P J Ousset; S Andrieu
Journal:  J Prev Alzheimers Dis       Date:  2014-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.